Clinical trials: Diabetes Mellitus Type 2 in Obese
Type 2 Diabetes Mellitus (T2DM)
A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM
To evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of ALN-KHK and to evaluate the safety, tolerability, efficacy, PK and PD of multiple doses of KHK.
- Trial name
- NCT05761301
- Testing
- ALN-KHK
- Where
- 15 sites in United States, Canada
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Type 2 Diabetes Mellitus, Obesity
Form of Dairy Products on Satiety, Food Intake and Post-meal Glycaemia in Young and Older Adults
The proposed study is planned to determine the potential role for regular fat dairy products in short-term metabolic control in younger and older adults and the metabolic flexibility in response to food components, which are…
- Trial name
- NCT02491801
- Testing
- Dietary intervention
- Where
- Canada
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Type 2 Diabetes Mellitus, Diabetic Kidney Disease
Low Carbohydrate Diet in Diabetic Kidney Disease
The current population of type 2 diabetes mellitus (T2DM) worldwide is over 200 million and Malaysia contributes to 1.2% of that number.
- Conditions
- Type 2 Diabetes Mellitus, Diabetic Kidney Disease, Obesity
- Trial name
- NCT04931030
- Testing
- Dietary advice
- Where
- Malaysia
- Volunteers
- 30 people
- Sponsor
- Universiti Teknologi Mara
Obesity, Overweight
Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight
The main objective of this study is to assess participants' ability to self-administer subcutaneous doses of maridebart cafraglutide at home using an autoinjector device.
- Trial name
- MARITIME-PEN (NCT07871409)
- Testing
- Maridebart cafraglutide, Autoinjector
- Where
- United States
- Volunteers
- 230 people
- Sponsor
- Amgen
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
The goal of this clinical trial is to determine whether Endoscopic Sleeve Gastroplasty (ESG)-induced weight loss can improve glycemic outcomes and alter the trajectory toward insulin dependence in adults with obesity and…
- Trial name
- MEASURE (NCT07639684)
- Testing
- ESG with OverStitch
- Volunteers
- 50 people
- Sponsor
- Boston Scientific Corporation
Diabetes Mellitus, Type 2
C-Reactive Protein (CRP) in Obese Diabetic Women
The purpose of this study is to determine whether treatment with rosuvastatin for 6 months in obese type 2 diabetic women will improve their lipid profiles and thus prevent the progression to cardiovascular disease.
- Trial name
- NCT00262548
- Testing
- Rosuvastatin; improvement of lipid profile
- Where
- Mexico
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
A Phase 2 study with two cohorts of differing doses designed to evaluate the efficacy, safety and pharmacokinetics (PK) of MEDI0382 in patients with Type 2 Diabetes Mellitus (T2DM).
- Trial name
- NCT03244800
- Testing
- MEDI0382
- Where
- 5 sites in Germany
- Volunteers
- 65 people
- Sponsor
- MedImmune LLC
Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
Drug Interactions From Simultaneous Administration Of Metformin And GSK189075 To Subjects With Type 2 Diabetes
GSK189075 is intended for use as a single treatment or in combination with other treatments for tye 2 diabetes mellitus (T2DM). Metformin is widely used in Europe and the USA for the treatment of T2DM.
- Trial name
- NCT00376038
- Testing
- GSK189075 oral tablets, metformin tablets
- Where
- Mexico
- Volunteers
- 13 people
- Sponsor
- GlaxoSmithKline
Healthy Volunteers, Overweight
First Research Study to Look at How Two Medicines, NNC0480-0389 and Semaglutide, Work Together in Healthy People, in People With High Body Weight and in People With Diabetes
The purpose of this study is to investigate how safe, and how well tolerated, the new study drug NNC0480-0389 is when it is given together with semaglutide.
- Conditions
- Healthy Volunteers, Overweight, Obesity, Diabetes Mellitus, Type 2
- Trial name
- NCT04259801
- Testing
- NNC0480-0389, Semaglutide
- Where
- Netherlands
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2, Obesity
A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM
The purpose of this study is to evaluate the efficacy and safety of ofirnoflast in combination with semaglutide in comparison to semaglutide alone in obese participants with T2DM.
- Trial name
- NCT07172867
- Testing
- HT-6184, Semaglutide 1 mg
- Where
- United Arab Emirates
- Sponsor
- Halia Therapeutics, Inc.
Type 2 Diabetes Mellitus
Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus
This is a Phase 1, randomized, placebo-controlled, double-blind (investigator- and participant-blinded), sponsor-open study of PF-07081532.
- Trial name
- NCT05158244
- Testing
- PF-07081532
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2, Insulin Resistance
Evaluation of Intra-Abdominal Fat Extraction Using HydraSolve T2D™ in Obese Subjects With Type 2 Diabetes
This study will investigate the safety and efficacy of the investigational use of the HydraSolve T2D™ System in improving blood glucose control and insulin resistance in patients with obesity (Class 1, BMI 30-39.9 kg/m2) and type…
- Trial name
- NCT03953963
- Testing
- HydraSolve T2D™
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Medality Medical
Weight Loss
VK2735 for Weight Management Phase 3
This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics…
- Trial name
- VANQUISH 1 (NCT07104500)
- Testing
- VK2735
- Where
- 137 sites in United States, Puerto Rico
- Volunteers
- 4,500 people
- Sponsor
- Viking Therapeutics, Inc.
Abdominal Obesity, Type 2 Diabetes
ORAL ANTIDIABETICS EFFECT ON VISCERAL FAT
Weight control is an essential part of treatment for type 2 diabetes (T2D) patients. Weight loss is associated with decreased haemoglobin A1c (A1c) levels.
- Trial name
- NCT05032001
- Testing
- Biguanide, DPP4 inhibitors, SGLT2 inhibitors
- Where
- Mexico
- Volunteers
- 30 people
- Sponsor
- Metabolic Research Unit
Type 2 Diabetes, Morbid Obesity
The Effect of a Gastric Bypass on Type 2 Diabetes in the Morbidly Obese Patient
Proof of concept, of RYGBP and its capabilities to cure type 2 diabetes (DM 2) and sleep apnea has already been recognized in the reports on weight loss surgery.
- Trial name
- NCT01086111
- Where
- Belgium
- Volunteers
- 30 people
- Sponsor
- University Hospital, Gasthuisberg
Obesity, Type 2 Diabetes
Characterization of Metabolic Biomarkers in Varying Subjects
Traditional dietary, lifestyle, behavioral and pharmacologic treatment strategies have proven relatively ineffective for treating obesity, and once metabolic abnormalities such as Type 2 Diabetes (T2D) develop, definitive…
- Trial name
- NCT01199692
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- CPL Associates
Overweight, Type 2 Diabetes
Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
The main purpose of this study is to investigate efficacy and safety of three doses of petrelintide versus placebo in participants with overweight or obesity and type 2 diabetes.
- Conditions
- Overweight, Type 2 Diabetes, Obesity
- Trial name
- NCT06926842
- Testing
- Petrelintide
- Where
- 48 sites in United States
- Volunteers
- 221 people
- Sponsor
- Zealand Pharma
Diabetes, Type 2 Diabetes (T2DM)
CGM Use in Non-insulin Patients With DM2
The U.S. Food and Drug Administration (FDA) has approved multiple Continuous Glucose Monitoring (CGM) devices from different manufacturers to be used as an aide in patients with type 1 and type 2 diabetes who require medications…
- Conditions
- Diabetes, Type 2 Diabetes (T2DM), Obesity Type 2 Diabetes Mellitus, Non Insulin Dependent Diabetes Mellitus
- Trial name
- CGM-DWI (NCT07128342)
- Testing
- CGM Group, FSBG group
- Volunteers
- 100 people
- Sponsor
- Milwaukee VA Medical Center
Type 2 Diabetes
Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes
The main objective of the study will be to test the hypothesis that treatment with Liraglutide will decrease ER stress and adipose tissue in obese patients with type 2 diabetes.
- Trial name
- NCT02344186
- Testing
- Liraglutide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Temple University
Diabetes Mellitus, Type 2
Mechanism Underlying Beta-cell Failure in Obese African Americans With History of Hyperglycemic Crises
Obesity is common in African American (AA) patients with newly diagnosed diabetes who present with diabetic ketoacidosis (DKA). Despite the presentation with severe symptoms of insulinopenia and ketoacidosis, clinical and…
- Trial name
- NCT00753142
- Testing
- Intralipid 20%, Glucose infusion
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Emory University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.